Keryx Biopharmaceuticals Company Profile (NASDAQ:KERX)

Keryx Biopharmaceuticals trades on the NASDAQ under the ticker symbol "KERX."

Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) posted its quarterly earnings data on Thursday, May, 4th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.18) by $0.03. The firm had revenue of $11.82 million for the quarter, compared to analyst estimates of $10.19 million. Keryx Biopharmaceuticals had a negative return on equity of 1,122.28% and a negative net margin of 387.12%. The firm's quarterly revenue was up 73.2% on a year-over-year basis. During the same period in the prior year, the company earned ($0.39) earnings per share. View Keryx Biopharmaceuticals' Earnings History.

9 brokers have issued 1-year price targets for Keryx Biopharmaceuticals' stock. Their predictions range from $7.00 to $10.00. On average, they anticipate Keryx Biopharmaceuticals' stock price to reach $8.60 in the next twelve months. View Analyst Ratings for Keryx Biopharmaceuticals.

Here are some recent quotes from research analysts about Keryx Biopharmaceuticals stock:

• 1. According to Zacks Investment Research, "Keryx intends to focus on the growth of Auryxia in the U.S. dialysis market. Meanwhile, the company’s label expansion efforts on Auryxia in the iron-deficiency anemia (IDA) indication seem to be encouraging, given that the IDA market holds great potential. The FDA accepted for review the supplemental New Drug Application (sNDA) for Auryxia tablets for the same indication and has set the Prescription Drug User Fee Act (PDUFA) target action date as Nov 6, 2017.  A potential approval should boost sales.. Moreover, shares of the company have outperformed the Medical-Biomed/Genetic Market  in year to date. However, considering that the company is heavily dependent on Auryxia for growth, any further interruption in the supply of Auryxia will hamper its growth trajectory, going forward." (7/17/2017)
• 2. Maxim Group analysts commented, "After recently announcing that the nation’s largest Medicare Part D plan sponsor has added Auryxia to its Medicare Part D plan formularies, the company today announced that they have secured formulary status at another large Medicare Part D sponsor and that now 95% of dialysis patients on phosphate binders across Medicare Part D and commercial insurance providers now have unrestricted access to Auryxia." (5/1/2017)
• 3. JMP Securities analysts commented, "Hogan Reward"The expert cited Keryx Biopharmaceuticals (NASDAQ: KERX)'s sulodexide as an example of a development-stage asset that failed such a confirmation in another kidney disease called diabetic nephropathy.The DUET study has rolled over onto the open-label portion, although the active control irbesartan will not be carried forward, thus it may be difficult to detect a treatment benefit."We believe that we will need to wait until year end to determine if the company can convince the FDA that an accelerated approval pathway can meet the agency's needs," analyst Liisa Bayko wrote in a note."Our sensitivity analysis shows that the stock currently reflects the sentiment that accelerated approval is unlikely," (9/8/2016)

Some companies that are related to Keryx Biopharmaceuticals include Lexicon Pharmaceuticals (LXRX), NovoCure Limited (NVCR), Array BioPharma (ARRY), Dermira (DERM), Acceleron Pharma (XLRN), Amarin Corporation PLC (AMRN), Xencor (XNCR), Clinigen Group PLC (CLIN), Insmed (INSM), Forward Pharma A/S (FWP), Synergy Pharmaceuticals (SGYP), Achaogen (AKAO), Acorda Therapeutics (ACOR), Aduro Biotech (ADRO), Omeros Corporation (OMER), Ascendis Pharma A/S (ASND), Insys Therapeutics (INSY) and ZIOPHARM Oncology (ZIOP).

Keryx Biopharmaceuticals' management team includes the folowing people:

• Gregory Paul Madison, Chief Executive Officer, Director
• Scott A. Holmes, Chief Financial Officer, Treasurer
• Christine A. Carberry, Chief Operating Officer
• Douglas M. Jermasek, Vice President of Marketing and Strategy
• Brian R. Adams, General Counsel, Secretary
• Lora Pike, Senior Director
• John F. Neylan, Chief Medical Officer
• John P. Butler, Independent Director
• Kevin J. Cameron, Independent Director
• Steven C. Gilman Ph.D., Independent Director

Keryx Biopharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Bank of Montreal Can (0.06%), Baldwin Brothers Inc. MA (0.04%) and Creative Planning (0.03%). Company insiders that own Keryx Biopharmaceuticals stock include Brian Adams, Greg Madison, John F Neylan and Scott A Holmes. View Institutional Ownership Trends for Keryx Biopharmaceuticals.

Shares of Keryx Biopharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Keryx Biopharmaceuticals stock can currently be purchased for approximately $7.17.